Cost-Effectiveness Analysis of Treatment Acute Deep Vein Thrombosis in Clinic of Vascular Surgery Sarajevo

Haris Vukas; Samra KadiÄ‡-Vukas; Adis SalihbegoviÄ‡; Muhamed DjedoviÄ‡; Dragan TotiÄ‡; Haris VraniÄ‡; Amel HadÅ¾imehmedagiÄ‡

doi:10.3889/oamjms.2017.139

Authors

Haris Vukas Clinic of Vascular Surgery Sarajevo, Clinical Centre University of Sarajevo, ÄŒekaluÅ¡a 88, Sarajevo
Samra KadiÄ‡-Vukas Department of Neurology Cantonal Hospital Zenica, Crkvice 76, Zenica
Adis SalihbegoviÄ‡ Institute of Forensic Medicine and Forensic Toxicology Medical Faculty in Sarajevo, ÄŒekaluÅ¡a 90, Sarajevo
Muhamed DjedoviÄ‡ Clinic of Vascular Surgery Sarajevo, Clinical Centre University of Sarajevo, ÄŒekaluÅ¡a 88, Sarajevo
Dragan TotiÄ‡ Clinic of Vascular Surgery Sarajevo, Clinical Centre University of Sarajevo, ÄŒekaluÅ¡a 88, Sarajevo
Haris VraniÄ‡ Clinic of Vascular Surgery Sarajevo, Clinical Centre University of Sarajevo, ÄŒekaluÅ¡a 88, Sarajevo
Amel HadÅ¾imehmedagiÄ‡ Clinic of Vascular Surgery Sarajevo, Clinical Centre University of Sarajevo, ÄŒekaluÅ¡a 88, Sarajevo

DOI:

https://doi.org/10.3889/oamjms.2017.139

Keywords:

acute deep vein thrombosis (ADVT), cost, un-fractionated heparin (UFH), low molecular weight heparin (LMWH)

Abstract

AIM: To compare hospital costs of acute deep vein thrombosis (ADVT) treatment in two periods of time. Evidence of repercussions on reducing costs during successful treatment. Attention was given to the necessity, costs and effectiveness of diagnostic procedures, treatment and complications.

METHODS: A retrospective analysis of data obtained from patients medical history in a period from 2000 to 2016. Model management and safe practice of ADVT care consisted of clinical examination, laboratory, colour Doppler and invasive diagnostics. In a treatment was used continuous infusion un-fractionated heparin for 40 patients from 2000th till 2006th and low molecular weight heparin for 40 patients from 2006th till 2016th. All patients were converted to oral anticoagulants.

RESULTS: When we look at the overall picture of improving the management model, safe practices and economic rationalization, we conclude that we offer better health service for the patients with ADVT at the moment, which relies on proven medical treatment trends. While we do not forget responsibility towards a society of which depends on treatment funding.

CONCLUSION: The implementation of a conceptually new model of management of ADVT did not contribute rise of the desired outcomes, but it justified the positive economic viability of introduced changes at the Clinic of Vascular surgery than the previous concept.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

WHO Europe, Health 21 - health for all into the 21st century, European Health for All, series No. 5 Copenhagen: WHO, 1999.

Council of Europe, http://www.cm.coe.int/ta/rec/1997/97r17.html

O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ. 1994;150:1083â€“1090. PMid:8137188 PMCid:PMC1486381

Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-veinthrombosis after total hip replacement surgery. Arch Intern Med. 1995;155:757â€“764. https://doi.org/10.1001/archinte.1995.00430070117013 PMid:7695464

Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999;130(10):789-799. https://doi.org/10.7326/0003-4819-130-10-199905180-00002 PMid:10366368

Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care. 1991;7:561â€“73. https://doi.org/10.1017/S0266462300007121

Ellwein LB, Drummond MF. Economic analysis alongside clinical trials: bias in the assessment of economic outcomes. Int J Technol Assess Health Care. 1996;12:691â€“7. https://doi.org/10.1017/S0266462300010977

Creekmore FM, Oderda GM, Pendleton RC, Brixner DI. Incidence and economic implications of heparin-induced throm-bocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy. 2006;26(10):1438-1445. https://doi.org/10.1592/phco.26.10.1438 PMid:16999654

Schadlich PK, Kentsch M, Weber M, et al. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany. Pharmacoeconomics. 2006;24(6):571-591. https://doi.org/10.2165/00019053-200624060-00005 PMid:16761905

Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.N Engl J Med. 1996;334(11):677-681. https://doi.org/10.1056/NEJM199603143341101 PMid:8594425

Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2):146-153. https://doi.org/10.1056/NEJMoa025313 PMid:12853587

Pannucci CJ1, Swistun L, MacDonald JK, Henke PK, Brooke BS. Individualized Venous Thromboembolism Risk Stratification Using the 2005 Caprini Score to Identify the Benefits and Harms of Chemoprophylaxis in Surgical Patients: A Meta-analysis. Ann Surg. 2017.